What Cobenfy Is and Why the Mechanism Matters

Cobenfy (xanomeline-trospium chloride), developed by Karuna Therapeutics, is the first approved muscarinic receptor agonist for schizophrenia — a mechanistic departure from the dopamine D2 antagonism that has defined antipsychotic therapy for more than six decades. The combination pairs xanomeline, a centrally active muscarinic agonist with preferential activity at M1 and M4 receptor subtypes, with trospium chloride, a peripherally restricted muscarinic antagonist whose role is to block the cholinergic adverse effects that previously made xanomeline clinically unviable as a monotherapy.

The mechanistic rationale rests on the distinct roles of M1 and M4 receptors in brain circuits implicated in schizophrenia. M1 receptors are highly expressed in the prefrontal cortex and hippocampus — regions central to working memory and cognitive control — while M4 receptors modulate dopaminergic neurotransmission in the striatum, a pathway directly relevant to positive symptoms such as hallucinations and delusions. By activating both subtypes centrally while sparing peripheral muscarinic receptors, Cobenfy aims to achieve antipsychotic efficacy without the metabolic, extrapyramidal, or sedative liabilities of existing agents.

Patent filings from Karuna Therapeutics cover not only the fixed-dose combination and its dosing regimens but also modified-release formulations designed to further optimise the pharmacokinetic profile of xanomeline and potentially reduce residual adverse events. These formulation patents, published in 2023, extend the intellectual property perimeter well beyond the core composition claims and represent a significant barrier to biosimilar or generic entry.

The Patent Landscape: Who Is Racing to Follow Cobenfy

Cobenfy’s approval has validated the muscarinic agonist mechanism so decisively that at least seven major pharmaceutical companies have filed substantive patent applications in the M1/M4 agonist space for CNS disorders between 2022 and 2025. The competitive field is not pursuing xanomeline itself — Karuna’s composition and method claims create a robust exclusionary zone — but is instead developing structurally distinct selective M4 agonists, selective M1 agonists, and M1/M4 dual agonists that aim to improve upon Cobenfy’s tolerability, selectivity, and oral bioavailability profile.

Eli Lilly has filed three distinct structural series of selective M4 agonists: substituted quinoxalines (2023), substituted imidazo[1,2-a]pyridines (2024), and substituted pyridopyrimidines (2024). The diversity of scaffolds suggests a broad medicinal chemistry campaign aimed at identifying a development candidate with optimal selectivity, brain penetration, and oral bioavailability — characteristics that would differentiate from xanomeline’s non-selective muscarinic profile.

Cerevel Therapeutics has similarly filed across both M4-selective and M1-selective series, as well as compounds with activity at both subtypes. AbbVie’s filings span M4 receptor agonists and M1/M4 dual agonists, while Janssen Pharmaceutica has disclosed novel heterocyclic M4 agonist series. H. Lundbeck and Astellas Pharma each have disclosed M4/M1 agonist compounds, and Vanderbilt University — a historically important academic contributor to muscarinic pharmacology — has published positive allosteric modulator (PAM) patents for both M1 and M4 receptors, representing a mechanistically distinct approach that could offer improved subtype selectivity without the agonist-related adverse effect profile.

Bristol-Myers Squibb, which acquired Karuna Therapeutics and thereby Cobenfy, has itself filed new composition-of-matter patents covering M1/M4-preferring muscarinic receptor agonists distinct from xanomeline, signalling an intent to build a next-generation successor programme within the same mechanistic class. These filings, published in mid-2024, cover methods for treating both schizophrenia and Alzheimer’s disease, and explicitly contemplate combination with antipsychotic drugs — a potential differentiation strategy from Cobenfy’s current monotherapy positioning.

“The muscarinic agonist patent landscape has expanded from a single approved agent to a field of more than seven competing companies filing structurally distinct M1, M4, and dual-agonist series — all within a three-year window following Cobenfy’s approval.”

Extending the Franchise: Alzheimer’s Disease Psychosis as the Next Battleground

Karuna Therapeutics has filed dedicated patent applications covering the use of KarXT (xanomeline-trospium) for Alzheimer’s Disease Psychosis (ADP) — a distinct indication from schizophrenia that affects an estimated 30–50% of people with Alzheimer’s disease and currently has no FDA-approved pharmacological treatment specifically indicated for it, according to data from the National Institutes of Health. These filings, published in both US and international (PCT/EP) jurisdictions in 2023, specifically target the symptoms of delusions and hallucinations in the Alzheimer’s population.

The strategic logic is compelling: Alzheimer’s disease psychosis represents a large and underserved patient population where the non-dopaminergic mechanism of xanomeline may offer particular advantages. Existing antipsychotics carry an FDA black-box warning for increased mortality risk in elderly patients with dementia-related psychosis — a label that Cobenfy, with its distinct mechanism, does not share. If clinical trials in ADP confirm efficacy and an acceptable safety profile in this older, more medically complex population, the addressable market for the xanomeline-trospium franchise would expand substantially.

Bristol-Myers Squibb’s own next-generation M1/M4-preferring agonist filings, published in 2024, also explicitly cover Alzheimer’s disease — suggesting that even the innovator company is hedging against the possibility that a structurally distinct successor molecule could offer advantages over xanomeline in this population, particularly with respect to selectivity and tolerability. According to the World Health Organization, approximately 55 million people worldwide live with dementia, with Alzheimer’s disease accounting for 60–70% of cases — a patient population where psychosis is a major driver of hospitalisation and caregiver burden.

Beyond Positive Symptoms: Negative and Cognitive Targets Reshape the Competitive Picture

A defining feature of Cobenfy’s clinical and patent strategy is its explicit targeting of all three symptom domains of schizophrenia — positive, negative, and cognitive — rather than positive symptoms alone. Existing antipsychotics have largely failed to address negative symptoms (social withdrawal, flat affect, avolition) and cognitive impairment, which are the primary determinants of long-term functional outcomes and quality of life for people with schizophrenia, as documented in research published through Nature and peer-reviewed psychiatry literature.

Separate Karuna Therapeutics patent applications address negative symptoms and cognitive impairment associated with schizophrenia (CIAS) as distinct claims. The CIAS filings are particularly detailed, specifying improvements across seven cognitive domains: processing speed, working memory, attention/vigilance, verbal learning, visual learning, reasoning and problem solving, and social cognition. This granularity is significant because it establishes method-of-treatment claims that could support additional regulatory labelling for cognitive outcomes — a commercially valuable differentiation if clinical data support it.

The competitive pipeline’s focus on selective M4 agonists — particularly from Eli Lilly, Cerevel, AbbVie, and Janssen — reflects a hypothesis that M4 selectivity may deliver antipsychotic efficacy with fewer cholinergic adverse effects than the non-selective xanomeline, potentially eliminating the need for a co-formulated peripheral antagonist like trospium. If validated clinically, a once-daily oral selective M4 agonist without the complexity of a fixed-dose combination could represent a meaningful commercial challenge to Cobenfy, particularly in markets where simpler dosing regimens drive prescriber preference.

Vanderbilt University’s positive allosteric modulator (PAM) approach for M1 and M4 receptors represents a third mechanistic strategy: rather than directly activating receptors, PAMs potentiate endogenous acetylcholine signalling only when and where acetylcholine is released, which theoretically provides more physiologically appropriate receptor activation and further reduces the risk of receptor desensitisation or adverse effects from tonic agonism. According to WIPO patent data, academic institutions such as Vanderbilt continue to be significant sources of early-stage innovation in muscarinic pharmacology, with filings in both M1 and M4 PAM series published in 2024.

Competitive Readouts and Strategic Implications for 2026

The 2026 competitive landscape in the muscarinic agonist space will be shaped by three converging dynamics: clinical trial readouts from next-generation selective M4 and M1/M4 programmes, Cobenfy’s own data from Alzheimer’s Disease Psychosis trials, and the ongoing consolidation of intellectual property positions as composition-of-matter claims are granted or challenged across major jurisdictions.

For companies developing selective M4 agonists, the critical question is whether receptor selectivity translates into a clinically meaningful tolerability advantage over xanomeline-trospium — and whether that advantage is sufficient to offset Cobenfy’s first-mover position, established prescriber familiarity, and the extensive safety database that will accumulate with post-market experience. The patent record suggests that Eli Lilly, with three distinct M4 scaffold series filed between 2023 and 2024, is the most advanced in terms of medicinal chemistry diversification among the pure-play M4 programmes.

For Karuna/BMS, the Alzheimer’s Disease Psychosis indication represents the most significant near-term value creation opportunity. The absence of an approved pharmacological treatment specifically indicated for ADP — combined with the regulatory and safety complications surrounding existing antipsychotics in elderly dementia patients — creates a potential regulatory pathway where Cobenfy’s non-dopaminergic mechanism could be particularly advantageous. The dedicated ADP patent filings, covering both US and international jurisdictions, position the franchise for this expansion.

The Mindset Pharma patent (US11617758B2, granted 2023) introduces a further dimension: the combination of muscarinic agonists with serotonergic psychedelic compounds for psychosis and schizophrenia. While this approach is at an early stage relative to the selective M4 and M1/M4 programmes, it illustrates the breadth of mechanistic hypotheses now being pursued under the broader muscarinic agonist umbrella — and the extent to which Cobenfy’s approval has legitimised the class for further investment.

Suven Life Sciences has filed a patent covering xanomeline in combination with peripheral muscarinic antagonists other than trospium — including pirenzepine, solifenacin, and revefenacin — which could represent a strategy to develop a Cobenfy-adjacent product with a differentiated peripheral blocker component. The strategic and IP implications of such filings will depend on the scope of Karuna/BMS’s granted claims and their enforceability in key markets, a question that European Patent Office and USPTO examination outcomes will progressively clarify through 2026 and beyond.

The overall picture heading into 2026 is one of a rapidly maturing competitive field in which the muscarinic agonist mechanism for schizophrenia and Alzheimer’s psychosis has moved from a single validated agent to a multi-company race across receptor subtypes, chemical scaffolds, formulation strategies, and indication expansions. The patent record, with more than 481 documents identified in the muscarinic agonist CNS space, reflects the scale of investment that Cobenfy’s approval has catalysed — and the scale of the competitive challenge that Karuna/BMS will face as next-generation programmes approach clinical proof-of-concept readouts.